TY - JOUR
T1 - Outcomes of controlled human malaria infection after BCG vaccination
AU - Walk, Jona
AU - de Bree, L. Charlotte J.
AU - Graumans, Wouter
AU - Stoter, Rianne
AU - van Gemert, Geert Jan
AU - van de Vegte-Bolmer, Marga
AU - Teelen, Karina
AU - Hermsen, Cornelus C.
AU - Arts, Rob J.W.
AU - Behet, Marije C.
AU - Keramati, Farid
AU - Moorlag, Simone J.C.F.M.
AU - Yang, Annie S.P.
AU - van Crevel, Reinout
AU - Aaby, Peter
AU - de Mast, Quirijn
AU - van der Ven, André J.A.M.
AU - Stabell Benn, Christine
AU - Netea, Mihai G.
AU - Sauerwein, Robert W.
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Recent evidence suggests that certain vaccines, including Bacillus-Calmette Guérin (BCG), can induce changes in the innate immune system with non-specific memory characteristics, termed ‘trained immunity’. Here we present the results of a randomised, controlled phase 1 clinical trial in 20 healthy male and female volunteers to evaluate the induction of immunity and protective efficacy of the anti-tuberculosis BCG vaccine against a controlled human malaria infection. After malaria challenge infection, BCG vaccinated volunteers present with earlier and more severe clinical adverse events, and have significantly earlier expression of NK cell activation markers and a trend towards earlier phenotypic monocyte activation. Furthermore, parasitemia in BCG vaccinated volunteers is inversely correlated with increased phenotypic NK cell and monocyte activation. The combined data demonstrate that BCG vaccination alters the clinical and immunological response to malaria, and form an impetus to further explore its potential in strategies for clinical malaria vaccine development.
AB - Recent evidence suggests that certain vaccines, including Bacillus-Calmette Guérin (BCG), can induce changes in the innate immune system with non-specific memory characteristics, termed ‘trained immunity’. Here we present the results of a randomised, controlled phase 1 clinical trial in 20 healthy male and female volunteers to evaluate the induction of immunity and protective efficacy of the anti-tuberculosis BCG vaccine against a controlled human malaria infection. After malaria challenge infection, BCG vaccinated volunteers present with earlier and more severe clinical adverse events, and have significantly earlier expression of NK cell activation markers and a trend towards earlier phenotypic monocyte activation. Furthermore, parasitemia in BCG vaccinated volunteers is inversely correlated with increased phenotypic NK cell and monocyte activation. The combined data demonstrate that BCG vaccination alters the clinical and immunological response to malaria, and form an impetus to further explore its potential in strategies for clinical malaria vaccine development.
UR - http://www.scopus.com/inward/record.url?scp=85061769116&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-08659-3
DO - 10.1038/s41467-019-08659-3
M3 - Article
C2 - 30787276
AN - SCOPUS:85061769116
SN - 2041-1723
VL - 10
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 874
ER -